Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details)

v3.21.2
Organization, Plan of Business Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Feb. 08, 2019
Jun. 30, 2021
Dec. 31, 2020
Nov. 12, 2018
Accumulated deficit   $ 75,215 $ 73,268  
Cash and cash equivalents   1,121 $ 3,132  
Contractual milestone payments   $ 5,000    
Line of Credit [Member]        
Interim Financing Amount $ 7,000      
Invagen Pharmaceuticals Inc [Member]        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned       $ 35,000
Percentage of equity interest agreed to acquire in first stage       33.30%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount       $ 180,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Share Price $ 6.00      
Business acquisition shares acquisition for net proceeds $ 31,500      
Invagen Pharmaceuticals Inc [Member] | Invagen Pharmaceuticals Inc [Member]        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%